SCHEMBL24196566

SCHEMBL24196566

CCCCC(=O)c1cc2cc(F)ccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.59
PDPK1 O15530 1/20 0.59
ALDH1A1 P00352 1/20 0.59
LMNA P02545 1/20 0.59
HPGD P15428 1/20 0.59
TSHR P16473 1/20 0.59
NFKB1 P19838 1/20 0.59
APEX1 P27695 1/20 0.59
CYP2C19 P33261 1/20 0.59
HSD17B10 Q99714 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
FLT3 P36888 6/20 0.54
IDO1 P14902 1/20 0.52
HDAC3 O15379 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
HTR7 P34969 1/20 0.50
HRH4 Q9H3N8 1/20 0.50
HDAC4 P56524 1/20 0.50
HDAC7 Q8WUI4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30270465 1.00 KDM4E (0.59) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL30270438 0.91 KDM4E (0.62) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL24196936 0.91 KDM4E (0.62) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL24196169 0.85 KDM4E (0.66) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL30270477 0.85 KDM4E (0.66) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL2642778 0.83 F7 (0.59) FLT3IDO1HRH4
SCHEMBL22529428 0.83 FLT3 (0.52) KDM4EALDH1A1FLT3IDO1HDAC3
SCHEMBL21600656 0.80 KDM4E (0.68) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL2735804 0.80 ATM (0.56) KDM4EPDPK1ALDH1A1LMNAHPGD
SCHEMBL9789000 0.79 KDM4E (0.66) KDM4EPDPK1ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2026-03-10 US disclosed
EP-4175718-B1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIV CLAUDE BERNARD LYON (FR) 2024-10-02 EP disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
EP-4175718-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) 2023-05-10 EP disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed
WO-2022008475-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2022-01-13 WO disclosed
WO-2022008475-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2022-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570632-B2 Indole derivatives and uses thereof for treating a cancer CKS2, CSNK2A3, CSNK1A1L KDM4E 2594/4885PDPK1 1292/4885ALDH1A1 1571/4885
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 KDM4E 1643/4885PDPK1 352/4885ALDH1A1 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.